OBJECTIVE:

The objective was to evaluate efficacy and safety of rapid, large-dose intravenous (IV) administration of ferric carboxymaltose in correcting iron deficiency anemia due to abnormal uterine bleeding.

MATERIAL AND METHODS:

Quasi-experimental study of intervention, not controlled, with the variety before and after a single group (pretest-posttest) carried out in the Hospital Río de la Loza, Mexico, between May 2014 and September 2018. Inclusion criteria: patients 18 years of age or older with anemia and severe abnormal uterine hemorrhage. Exclusion criteria: transfusion of erythrocyte concentrates or administration of parenteral iron in the eight weeks prior to the study, etc. Study variables: hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin concentration, platelets and concentrations of ferritin and platelets.

RESULTS:

13 patients of 18 obtained an increase of 2 g/dL or greater of hemoglobin, 9 of 18 obtained an increase of 2.5 or greater and only 7 of 18 obtained an increase of 3g/dL or greater, the increases were dependent on the administered dose. The average final serum ferritin was 33.44 mcg/L. There were no serious adverse effects reported.

CONCLUSIONS:

The use of iron carboxymaltose intravenously at high doses is a safe treatment in the correction of iron deficiency anemia secondary to abnormal uterine hemorrhage and in the replenishment of iron stores.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )